Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Provided By GlobeNewswire
Last update: May 12, 2025
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025.
Read more at globenewswire.comNASDAQ:AVTX (7/22/2025, 1:46:45 PM)
6.7
-0.03 (-0.45%)
Find more stocks in the Stock Screener
